ERBB2 and breast cancer: When further using HR status to group breast cancer into subtypes, the HER2-zero, HER2-low, and HER2-positive subtypes comprised 17.0% (23), 68.1% (92), and 14.8% (20) of HR-positive recurrent tumors, respectively.